Gemmer Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Gemmer Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-594	Closed	-$14K	–	1442
2018 Q3	$14K	Hold	594	–	–	﹤0.01%	553
2018 Q2	$11K	Hold	594	–	–	﹤0.01%	671
2018 Q1	$10K	Hold	594	–	–	﹤0.01%	701
2017 Q4	$9K	Hold	594	–	–	﹤0.01%	762
2017 Q3	$11K	Hold	594	–	–	﹤0.01%	637
2017 Q2	$10K	Hold	594	–	–	﹤0.01%	660
2017 Q1	$8K	Hold	594	–	–	﹤0.01%	765
2016 Q4	$9K	Hold	594	–	–	﹤0.01%	673
2016 Q3	$10K	Hold	594	–	–	0.01%	613
2016 Q2	$7K	Hold	594	–	–	﹤0.01%	749
2016 Q1	$4K	Hold	594	–	–	﹤0.01%	912
2015 Q4	$6K	Hold	594	–	–	﹤0.01%	789
2015 Q3	$7K	Hold	594	–	–	﹤0.01%	689
2015 Q2	$8K	Hold	594	–	–	﹤0.01%	665
2015 Q1	$6K	Buy	594 +330	+125%	+$3.73K	﹤0.01%	841
2014 Q4	$4K	Sell	264 -263	-50%	-$3.11K	﹤0.01%	969
2014 Q3	$5K	Hold	527	–	–	﹤0.01%	887
2014 Q2	$9K	Hold	527	–	–	0.01%	663
2014 Q1	$9K	Buy	+527	New	+$7.49K	0.01%	638

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Gemmer Asset Management's VNDA Position: Q4 2018 in Review

Gemmer Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 594 shares — an estimated $14K sold.

Gemmer Asset Management first reported a position in VNDA in Q1 2014 and held it in 19 quarters. The position peaked at $14K in Q3 2018. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

Gemmer Asset Management reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Gemmer Asset Management sold 594 Vanda Pharmaceuticals shares in Q4 2018, an estimated $14K.
Gemmer Asset Management first reported a position in Vanda Pharmaceuticals in Q1 2014 and held it in 19 quarters.
Gemmer Asset Management's Vanda Pharmaceuticals position peaked at $14K in Q3 2018.
186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Gemmer Asset Management's 13F filing for Q4 2018, filed 18 Jan 2019.